🔗 Share this article

Ex-government leader Rishi Sunak has reinforced his call for a focused screening programme for prostate cancer.

In a recently conducted interview, he declared being "persuaded of the immediate need" of implementing such a initiative that would be economical, deliverable and "preserve numerous lives".

These comments surface as the National Screening Advisory Body reviews its decision from five years ago declining to suggest standard examination.

Media reports indicate the authority may uphold its existing position.

Athlete Adds Voice to Campaign

Olympic cycling champion Chris Hoy, who has advanced prostate cancer, wants younger men to be screened.

He recommends decreasing the age threshold for requesting a prostate-specific antigen blood test.

Currently, it is not routinely offered to asymptomatic males who are below fifty.

The PSA examination remains debated nevertheless. Levels can increase for factors apart from cancer, such as infections, resulting in false positives.

Skeptics argue this can lead to unwarranted procedures and complications.

Focused Testing Proposal

The suggested examination system would target males between 45 and 69 with a hereditary background of prostate gland cancer and men of African descent, who face twice the likelihood.

This population includes around 1.3 million males in the United Kingdom.

Research projections suggest the system would cost £25 million a year - or about £18 per patient - similar to intestinal and breast screening.

The projection involves one-fifth of eligible men would be contacted annually, with a nearly three-quarters response rate.

Diagnostic activity (scans and biopsies) would need to increase by 23%, with only a moderate growth in medical workforce, according to the study.

Medical Community Reaction

Some medical experts remain sceptical about the benefit of examination.

They assert there is still a risk that men will be medically managed for the disease when it is potentially overtreated and will then have to live with side effects such as bladder issues and impotence.

One respected urology specialist remarked that "The challenge is we can often detect abnormalities that doesn't need to be managed and we end up causing harm...and my concern at the moment is that harm to benefit ratio isn't quite right."

Individual Perspectives

Personal stories are also affecting the conversation.

A particular instance features a 66-year-old who, after asking for a blood examination, was diagnosed with the condition at the time of 59 and was advised it had metastasized to his pelvis.

He has since received chemotherapy, radiation treatment and hormone treatment but remains incurable.

The patient endorses screening for those who are genetically predisposed.

"This is essential to me because of my sons – they are in their late thirties and early forties – I want them screened as promptly. If I had been screened at fifty I am sure I would not be in the situation I am currently," he commented.

Next Steps

The Screening Advisory Body will have to weigh up the evidence and viewpoints.

While the new report says the consequences for staffing and accessibility of a screening programme would be manageable, opposing voices have argued that it would take scanning capacity away from individuals being treated for other conditions.

The continuing debate highlights the multifaceted balance between early detection and potential unnecessary management in prostate cancer management.